Wegovy 0.25mg dose per click: the starting-pen myth, corrected

The biggest misconception: 0.25mg is not the dose that produces weight loss

A question our prescribers hear most weeks goes roughly like this: "I've been on 0.25mg for a month and nothing's happening, is the dose wrong?" The short answer is that 0.25mg was never intended to drive weight loss. It is a tolerability dose. Its purpose is to introduce your gut to a GLP-1 receptor agonist gradually, reducing the likelihood of nausea and vomiting that can accompany faster escalation.

The NHS medicines information for semaglutide confirms that the 0.25mg injection is the starting point in a stepped schedule, titrated upward by the prescriber (typically at roughly four-week intervals) until you reach the maintenance dose your clinical picture supports. The NHS semaglutide patient page sets this out plainly, and it's worth reading before your first pen arrives.

So if you've been searching for what one click at 0.25mg actually delivers, the factual answer is: a single 0.25mg subcutaneous dose. The clinical significance of that number is that it keeps the first few weeks manageable, not that it does the heavy lifting. The therapeutic work begins once your prescriber moves you up the schedule. That process takes time, and rushing it doesn't help.

How the FlexTouch pen's click mechanism works at this dose

The Wegovy FlexTouch pen is a pre-filled, multi-dose device. Each pen is pre-set to the dose stated on the label, you don't dial a number or assemble anything. You press the injection button and hold it until the flow-stop click sounds, which confirms the full dose has been delivered. At the 0.25mg pen, that click releases 0.25mg of semaglutide in a fixed volume of solution.

This click-confirmation design is there for a reason: it removes the guesswork about whether you've injected the full dose. A detailed walkthrough of how doses differ across each pen in the schedule is available on our dose-per-click Wegovy guide, which covers the mechanics pen by pen.

Injection sites are the abdomen, thigh, or upper arm; rotate the spot each week to avoid tissue changes at a single site. Storage is refrigerated at 2–8°C until first use. The exact room-temperature window and full handling instructions live in the Patient Information Leaflet inside your box, those details are specific to the batch and should be read there, not paraphrased from a third-party source.

What changes as the dose increases beyond 0.25mg

The titration ladder for Wegovy runs 0.25mg, then 0.5mg, 1.0mg, 1.7mg, and 2.4mg as the established maintenance dose. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, a figure that only becomes relevant once patients have moved through the earlier steps and settled at the top of the standard schedule.

In 2026, the MHRA approved a higher maintenance dose of 7.2mg, first supplied as three 2.4mg pens per week, then as a dedicated single-dose pen from April 2026, for adults with BMI 30 or above. Trial data reported around 20.7% average weight loss over 72 weeks at this dose, which narrows the gap with tirzepatide (Mounjaro). Whether you're ever a candidate for 7.2mg is something only a prescriber can determine after reviewing your full clinical history; it is not a starting point for anyone.

For context on how the 0.25mg step sits alongside the rest of the schedule, the Wegovy dose-per-click chart maps out the full escalation sequence. If you want to read specifically about what the 2.4mg maintenance step involves, including how each click is measured at that dose, there is detail on our Wegovy 2.4mg dose-per-click page. If you want to read specifically about what the 1.0mg step involves, there is detail on our 1mg dose-per-click page.

Eligibility, clinical assessment, and what happens next

Wegovy is licensed for adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't decide approval; the prescriber weighs up the full picture, including any medicines you already take and relevant health history.

On the NHS, Wegovy is recommended by NICE (TA875) within specialist weight management services, and waiting lists can be long. Private routes through a regulated pharmacy don't require a referral. If you want to understand what the cost of private treatment involves and how it's structured, our Wegovy price comparison page covers the UK landscape honestly, including what a legitimate price should include.

The broader picture of how Wegovy works as a treatment (not just the dosing mechanics) is covered on our main Wegovy treatment page, and you can see how it sits alongside other options on our weight-loss treatments overview.

If you'd like a clinical assessment from a GPhC-registered prescriber, you can start your free consultation at any point. A real clinician reads every submission the same day.